EPT Disclosure - Amendment

17 May 2006 14:55

Deutsche Bank AG London17 May 2006 FORM 38.5 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS (Rule 38.5 of the City Code on Takeovers and Mergers) AMENDMENT - TOTAL NO OF SHARES BOUGHT 1. KEY INFORMATION Name of exempt principal trader Deutsche Bank AG London Company dealt in Cambridge Antibody Technology Group Plc Class of relevant security to which the dealings Ordinarybeing disclosed relate (Note 1) Date of dealing 15/05/2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities purchased Highest price paid (Note 3) Lowest price paid (Note 3) 861,691 £12.96261 £12.875 Total number of securities Sold Highest price received (Note 3) Lowest price received (Note 3) 10,814 £12.985 £12.92 (b) Derivatives transactions (other than options) Product name, e.g. Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3)CFD CFD Long 14,672 £12.96261CFD Long 55,520 £12.9129CFD Long 22,008 £12.939593CFD Long 90,759 £12.98187CFD Long 270,267 £12.9875CFD Long 100,000 £12.9945CFD Long 49,685 £12.98CFD Long 8,780 £12.939896CFD Short 4,000 £12.955CFD Short 1,540 £12.975CFD Short 3,407 £12.9811 (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product name,e.g. Writing, Number of Exercise Type, e.g. Expiry Option moneycall option selling, securities to price American, date paid/received purchasing, which the option European etc. per unit (Note varying etc. relates (Note 5) 3) (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the persondisclosing and any other person relating to the voting rights of any relevantsecurities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, this should bestated. ..................................................................... ..................................................................... Date of disclosure 17/05/2006Contact name Kelly-Jade LedwichTelephone number 0207 545 7804Name of offeree/offeror with which connected AstraZeneca PlcNature of connection (Note 6) Advisor to the offeror Notes The Notes on Form 38.5 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange